IMNM FY 2023 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M

Gross Profit

$14M100.0% margin

Operating Income

-$110M-781.4% margin

Net Income

-$107M-761.9% margin

EPS (Diluted)

$-5.38

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$149M

Total Liabilities

$29M

Stockholders' Equity

$120M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$0	—
Gross Profit	$14M	$0	—
Operating Income	-$110M	-$37M	-196.8%
Net Income	-$107M	-$37M	-189.5%